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Abstract
We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk fac-
tors for women of European ancestry, using 72 284 cases and 80 354 controls from the Breast Cancer Association Consortium.
Interactions were evaluated using standard logistic regression and a newly developed case-only method for breast cancer
risk overall and by estrogen receptor status. After accounting for multiple testing, we did not find evidence that per-standard
deviation PRS313 odds ratio differed across strata defined by individual risk factors. Goodness-of-fit tests did not reject the as-
sumption of a multiplicative model between PRS313 and each risk factor. Variation in projected absolute lifetime risk of breast
cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history) and,
on average, 17.5% higher in the highest vs lowest deciles of genetic risk. These findings have implications for risk prevention
for women at increased risk of breast cancer.
Precision prevention and early detection of cancer is a key aim
of cancer research and uses tools such as risk prediction models
for risk stratification (1,2). Many breast cancer risk prediction
models are focused either on classical risk factors or on inher-
ited mutations causing a moderate-to-high risk of cancer and
do not include risk associated with common susceptibility var-
iants (3). Modeling the joint associations of genetic and classical
risk factors could result in substantial improvement in risk
stratification and therefore improved prevention and screening
modalities for breast cancer (4–7).
Combined associations of single nucleotide polymorphisms
(SNPs) can be summarized by a polygenic risk score (PRS);
women in the top 1% of the newly derived 313-SNP PRS (PRS313)
have a fourfold increased risk of breast cancer than women at
population-average risk (8). Previous studies, which evaluated
combined associations between classical risk factors and breast
cancer PRS based on 77 SNPs (9) and 24 SNPs (10), found weak or
no evidence of departure from the multiplicative risk assump-
tion for overall breast cancer. In the current study, we extend
these analyses to assess the combined associations of the
PRS313 and classical risk factors using data from the Breast
Cancer Association Consortium (BCAC). This new PRS has been
validated by prospective studies and shown to be more predic-
tive than the previously reported 77-SNP PRS (11) for risk of
breast cancer overall as well as for estrogen receptor (ER)
subtype-specific breast cancer (8). Additionally, this study found
evidence of interaction for ER-positive disease between PRS313
and family history, indicating the need to consider the joint
effects of these 2 factors (8).
Detailed information on study samples, genetic data, and
risk factor data is provided in the Supplementary Materials
(available online). Briefly, we performed analyses using data
from women of European ancestry from 16 prospective cohorts,
14 population-based case-control studies, and 16
nonpopulation-based studies included in BCAC (Supplementary
Table 1, available online). Samples were genotyped using 2
arrays: iCOGS (12) and OncoArray (13–15). Risk factor data were
derived with respect to a reference age (date at diagnosis for
cases and date at interview for controls). Development of the
PRS is briefly explained in Supplementary Materials (available
online) (8). We standardized the PRS to have unit standard devi-
ation for the controls.
Departure from the assumption of multiplicative combined
effects of standardized PRS313 and each risk factor was assessed
using two methods: unconditional logistic regression model and
likelihood ratio test, and a newly developed case-only method,
which assumes independence between PRS and risk factors in the
underlying population and has greater efficiency compared with
logistic regression (16). Individual models were fitted for each PRS-
risk factor combination for overall and ER-specific breast cancer.
Models were adjusted for reference age, study, and corresponding
10 ancestry-informative principal components for each array.
Array-specific results were meta-analyzed using a fixed-effect in-
verse-variance weighted method. To evaluate global goodness-of-
fit of the multiplicative model between PRS313 and each risk factor,
we performed the Hosmer-Lemeshow test using population-based
studies. Moreover, we assessed goodness-of-fit at the extremes of
the distribution (tails) using a tail-based test (17). Using the iCARE-
BPC3model (4), we projected absolute lifetime risk of breast cancer
for 50-year-old white non-Hispanic US women up to aged 80years.
We assessed the distribution of risk because of classical (ie, men-
strual and reproductive and lifestyle) and modifiable risk factors,
respectively, within categories of risk defined by genetic factors (ie,
breast cancer family history and PRS313).
Associations between PRS313 and overall and ER-specific
breast cancer risk are likely to be overestimated because there
was substantial overlap between the SNP discovery samples
and our dataset (Supplementary Figure 1, available online). The
number of cases and controls varied for each risk factor, ranging
from 61 617 cases and 74 698 controls for ever parous to 14 576
cases and 19 640 controls for pack-years smoked for overall
breast cancer risk (Supplementary Table 2, available online).
Based on the population-based case-control and prospective co-
hort studies, the associations of the risk factors with overall and
ER subtype-specific breast cancer were of the expected magni-
tude and direction (Supplementary Table 3, available online).
After accounting for multiple testing using Bonferroni ad-
justment (Pint < .05/16¼ .003), none of the interactions between
PRS313 and any classical risk factor was statistically significant




































































































Table 1. Odds ratios and 95% confidence intervals for multiplicative interactions between the 313-SNP PRS (continuous) and classical risk factors of breast cancer, overall and by ER status
Risk factors Controls













Cases ORint (95% CI) Pint Cases ORint (95% CI) Pint Cases ORint (95% CI) Pint ORint (95% CI) Pint ORint (95% CI) Pint ORint (95% CI) Pint
Age at menarche (per
2 years)
64 087 52 1701.01 (0.99 to 1.03) .26 36 8201.01 (0.99 to 1.03) .29 8323 1.01 (0.98 to 1.04) .55 1.01 (1.00 to 1.02) .221.01 (0.99 to 1.02) .371.02 (0.99 to 1.06) .21
Ever parous (yes/no) 72 552 59 2980.97 (0.93 to 1.00) .07 41 8580.98 (0.94 to 1.02) .35 9273 0.98 (0.92 to 1.05) .57 0.97 (0.94 to 1.00) .080.99 (0.96 to 1.03) .721.00 (0.92 to 1.09) .97
Number of children
(1, 2, 3, 4)d
61 654 48 7861.00 (0.99 to 1.02) .96 34 6661.00 (0.99 to 1.02) .73 7552 0.99 (0.96 to 1.02) .53 1.01 (0.99 to 1.02) .381.01 (1.00 to 1.03) .111.00 (0.97 to 1.04) .90
Age at FFTP (per
5 years)d
53 042 41 6711.00 (0.99 to 1.02) .82 29 6011.00 (0.98 to 1.01) .68 6517 0.99 (0.96 to 1.02) .52 1.00 (0.98 to 1.01) .390.99 (0.97 to 1.00) .061.00 (0.97 to 1.03) .92
Breastfeeding (yes/no)d 37 568 34 1991.02 (0.98 to 1.06) .44 24 2731.01 (0.96 to 1.05) .81 5548 1.01 (0.95 to 1.08) .74 1.02 (0.99 to 1.05) .171.02 (0.98 to 1.06) .361.02 (0.95 to 1.11) .55
Duration of breast feed-
ing (per 12 mo)d
26 367 27 7411.00 (0.98 to 1.02) .71 19 3291.00 (0.97 to 1.02) .76 4669 0.99 (0.95 to 1.03) .57 1.01 (0.99 to 1.03) .321.01 (0.99 to 1.03) .570.99 (0.96 to 1.03) .77
Adult height (per 5 cm) 62 414 54 8470.99 (0.98 to 1.00) .07 38 7300.99 (0.98 to 1.00) .04 8682 1.00 (0.98 to 1.02) .77 1.00 (0.99 to 1.01) .920.99 (0.98 to 1.01) .291.01 (0.99 to 1.03) .48
Premenopausal BMI (per
5 kg/m2)e
15 610 12 8370.98 (0.95 to 1.00) .08 83540.99 (0.96 to 1.02) .48 2333 0.95 (0.91 to 1.00) .04 0.97 (0.94 to 1.00) .021.00 (0.96 to 1.03) .770.95 (0.89 to 1.01) .10
Postmenopausal BMI
(per 5 kg/m2)f
46 137 37 0881.01 (0.99 to 1.02) .49 27 3051.01 (0.99 to 1.02) .39 5260 1.01 (0.99 to 1.04) .36 1.01 (1.00 to 1.02) .291.01 (1.00 to 1.03) .080.99 (0.96 to 1.02) .45
Ever use of oral
contraceptives
(yes/no)
56 768 44 9791.01 (0.98 to 1.04) .63 31 6401.02 (0.98 to 1.05) .36 7061 1.02 (0.97 to 1.08) .42 0.99 (0.97 to 1.02) .451.00 (0.97 to 1.02) .751.01 (0.95 to 1.08) .73
Current use of EPT
(yes/no)f,g
20 896 19 0471.07 (1.01 to 1.14) .02 14 4651.06 (0.99 to 1.13) .08 2761 1.05 (0.92 to 1.19) .49 1.00 (0.96 to 1.04) .930.98 (0.93 to 1.03) .321.04 (0.91 to 1.18) .59
Current use of ET
(yes/no)f,g
20 716 18 7160.97 (0.91 to 1.03) .33 14 2010.96 (0.90 to 1.03) .28 2733 1.06 (0.94 to 1.20) .37 0.96 (0.91 to 1.01) .090.94 (0.89 to 0.99) .031.08 (0.95 to 1.23) .26
Alcohol consumption
(per 10 g/day)
16 851 14 4841.00 (0.97 to 1.02) .75 10 2530.98 (0.96 to 1.00) .07 2259 1.06 (1.01 to 1.11) .03 1.00 (0.99 to 1.02) .710.99 (0.97 to 1.01) .191.04 (1.00 to 1.08) .06
Current smoking
(yes/no)h
56 308 43 3031.04 (1.00 to 1.08) .07 30 4861.05 (1.00 to 1.10) .03 6813 1.05 (0.97 to 1.13) .25 1.02 (0.98 to 1.05) .421.02 (0.98 to 1.06) .401.03 (0.95 to 1.11) .52
Pack-years of smoking
(per 10 pack-years)i
15 990 11 7660.99 (0.98 to 1.01) .43 82680.99 (0.97 to 1.01) .19 1778 0.99 (0.96 to 1.02) .67 1.00 (0.99 to 1.01) .971.00 (0.99 to 1.01) .991.00 (0.97 to 1.03) .97
Family history in a
first-degree relative
(yes/no)j
50 955 42 0240.93 (0.89 to 0.96)3.00  10528 9090.93 (0.90 to 0.97)8.00  104 6921 0.93 (0.87 to 0.99) .03 — — — — — —
aNumber of cases are same for case-control and case-only method. PRS ¼ polygenic risk score; SNP ¼ single nucleotide polymorphisms; ORint ¼ interaction odds ratio (per SD of PRS313); CI ¼ confidence intervals; FFTP ¼ first full-
term pregnancy; BMI ¼ body mass index; EPT ¼ estrogen-progesterone therapy; ET ¼ estrogen-only therapy; ER ¼ estrogen receptor; MHT ¼ menopausal hormonal therapy.
bThe case-only analyses do not provide additional evidence to case-control analyses.




gModels used to assess association with the use of MHT have been further adjusted for former use of MHT and use of any other type MHT preparations.
hModels used to assess association with current smoking have been further adjusted for former smoking.
iAmong ever smoked.
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sided. The observed interaction between PRS313 and family his-
tory for ER-positive breast disease is consistent with what has
been previously published based on an overlapping dataset (8).
Such an interaction was also found for overall and ER-negative
breast cancer risk. There was no evidence for a clear dose-
response in the estimated ORs associated with classical risk fac-
tors when stratified by PRS percentiles (Supplementary Figures
2–4, available online). Neither global nor tail-based goodness-of-
fit tests supported departure from the multiplicative model for
any risk factor for both overall and ER-positive breast cancer
(Supplementary Table 4, available online). Goodness-of-fit tests
were not performed for ER-negative breast cancer because of
the relatively small sample size.
Lack of evidence for substantial departure from the multipli-
cative assumption between the PRS313 and risk factors using
this large study implies that the absolute risk associated with
each classical risk factor is greater for women with higher poly-
genic risk (5,18). This is illustrated by our projections, which
show that the lifetime risk due to classical risk factors was
higher with a wider variation across women who are at a higher
risk due to genetic factors (PRS313 and family history) (Figure 1,
a) and consistent with a recent study of body mass index com-
bined with a measure of familial risk based on multigenera-
tional family history (18). The predicted average lifetime risk
due to all classical risk factors for women in the lowest and
highest deciles of the genetic risk was 21.9% and 4.4%, respec-
tively, so the difference in risk was 17.5%. The difference in risk
between these 2 deciles associated with the subset of modifi-
able risk factors was 16.5% (Figure 1, b). However, the absolute
risk projections shown in Figure 1 should be viewed with cau-
tion because they assume perfect model calibration. In addition,
these absolute risk projections require validation.
Our analyses using the current PRS313 are based on a sample
size 3 times larger than that used in previously published BCAC
analyses (9), although the dataset for ER-negative breast cancer
is still limited. Our previous work on the PRS313 development (8)
and the current analyses is based on European ancestry and
may not be generalizable to other populations, highlighting the
need for more studies in populations of non-European or mixed
ancestry.
Overall, the combined associations of the newly developed
PRS313 and the classical risk factors on breast cancer risk are
well explained by a multiplicative model, except for family his-
tory, and will inform the development of overall and ER-specific
risk prediction models in the future. Most important, our find-
ings suggest that preventive strategies aimed at modifying indi-
vidual risk factors could have stronger impact on absolute risk
reduction for women at higher genetic risk.
Funding
This work was supported by following funding agencies.
BCAC is funded by Cancer Research UK [C1287/A16563,
C1287/A10118], the European Union’s Horizon 2020
Research and Innovation Programme (grant numbers
634935 and 633784 for BRIDGES and B-CAST respectively),
and by the European Communitys Seventh Framework
Programme under grant agreement number 223175 (grant
number HEALTH-F2-2009–223175) (COGS). The EU Horizon
2020 Research and Innovation Programme funding source
had no role in study design, data collection, data analysis,
data interpretation or writing of the report.
Genotyping of the OncoArray was funded by the NIH
Grant U19 CA148065, and Cancer UK Grant C1287/A16563
and the PERSPECTIVE project supported by the Government
of Canada through Genome Canada and the Canadian
Institutes of Health Research (grant GPH-129344) and, the
Ministère de l’Economie, Science et Innovation du Quebec
through Genome Quebec and the PSRSIIRI-701 grant, and
the Quebec Breast Cancer Foundation. Funding for the
iCOGS infrastructure came from: the European
Community’s Seventh Framework Programme under grant
agreement n 223175 (HEALTH-F2-2009–223175) (COGS),
Cancer Research UK (C1287/A10118, C1287/A10710, C12292/
A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/
A10692, C8197/A16565), the National Institutes of Health
(CA128978) and Post-Cancer GWAS initiative (1U19
CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-
ON initiative), the Department of Defence (W81XWH-10–1-
0341), the Canadian Institutes of Health Research (CIHR) for
the CIHR Team in Familial Risks of Breast Cancer, and
Komen Foundation for the Cure, the Breast Cancer Research
Foundation, and the Ovarian Cancer Research Fund. The
DRIVE Consortium was funded by U19 CA148065.
The Australian Breast Cancer Family Study (ABCFS) was
supported by grant UM1 CA164920 from the National Cancer
Institute (USA). The content of this manuscript does not
necessarily reflect the views or policies of the National
Cancer Institute or any of the collaborating centers in the
Breast Cancer Family Registry (BCFR), nor does mention of
trade names, commercial products, or organizations imply
endorsement by the USA Government or the BCFR. The
ABCFS was also supported by the National Health and
Medical Research Council of Australia, the New SouthWales
Cancer Council, the Victorian Health Promotion Foundation
(Australia) and the Victorian Breast Cancer Research
Consortium. J.L.H. is a National Health and Medical
Research Council (NHMRC) Senior Principal Research
Fellow. M.C.S. is a NHMRC Senior Research Fellow. The
ABCS study was supported by the Dutch Cancer Society
[grants NKI 2007–3839; 2009 4363]. The Australian Breast
Cancer Tissue Bank (ABCTB) was supported by the National
Health and Medical Research Council of Australia, The
Cancer Institute NSW and the National Breast Cancer
Foundation. The AHS study is supported by the intramural
research program of the National Institutes of Health, the
National Cancer Institute (grant number Z01-CP010119), and
the National Institute of Environmental Health Sciences
(grant number Z01-ES049030). The work of the BBCC was
partly funded by ELAN-Fond of the University Hospital of
Erlangen. The BCEES was funded by the National Health and
Medical Research Council, Australia and the Cancer Council
Western Australia and acknowledges funding from the
National Breast Cancer Foundation (JS). The BREast
Oncology GAlician Network (BREOGAN) is funded by Accion
Estrategica de Salud del Instituto de Salud Carlos III FIS PI12/
02125/Cofinanciado FEDER; Accion Estrategica de Salud del
Instituto de Salud Carlos III FIS Intrasalud (PI13/01136);
Programa Grupos Emergentes, Cancer Genetics Unit,
Instituto de Investigacion Biomedica Galicia Sur. Xerencia
de Xestion Integrada de Vigo-SERGAS, Instituto de Salud
Carlos III, Spain; Grant 10CSA012E, Consellerıa de Industria




































































































Figure 1. Distribution of absolute lifetime risk explained by (a) all classical risk factors and (b) modifiable classical risk factors within decile categories of genetic risk,
due to 313-variant polygenic risk score (PRS) and family history, for 50-year-old white non-Hispanic women in the United States before aged 80years. The solid hori-
zontal lines represent the mean risk within each decile, and the dashed horizontal line across the plot represents the population lifetime mean risk (10.9%). Lifetime
risk is estimated using the iCARE-BPC3 model and refers to absolute risk from aged 50 to 80 years. The genetic component includes the 313-variant PRS and breast can-
cer family history. The classical risk factor component includes the following risk factors: age at menarche, age at menopause, parity, age at first birth, height, body
mass index (BMI), alcohol intake, smoking status, ever and current use of hormone replacement therapy (HRT), and HRT type among ever users. The modifiable classi-
cal risk factor component includes BMI, ever or current use of HRT, smoking status, and alcohol consumption. Outliers defined as points beyond 1.5 times the inter-
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